DOCSLIB.ORG

1999 Generic Codes and Names in Numeric Order

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

1999 GENERIC CODES AND NAMES IN NUMERIC ORDER 50000 UNDETERMINED 50170 AMBENONIUM 50365 APROBARBITAL 50001 DIFENOXIN 50175 AMCINONIDE 50367 ARALIA 50002 LEVONORGESTREL 50178 AMDINOCILLIN 50370 ARGININE 50004 ACACIA 50180 AMIKACIN 50375 ARNICA TINCTURE 50005 ACETAMINOPHEN 50182 AMILORIDE 50378 AROMATIC ELIXIR 50008 ACEBUTOLOL 50183 AMINACRINE 50380 ASAFETIDA TINCTURE HYDROCHLORIDE 50185 AMINO ACIDS 50400 ASPARAGINASE 50015 ACETANILID 50190 AMINOACETIC ACID 50410 ASPIRIN 50018 ACETATE ION 50195 AMINOBENZOIC ACID 50418 ATENOLOL 50020 ACETAZOLAMIDE 50200 AMINOCAPROIC ACID 50419 ATRACURIUM BESYLATE 50025 ACETIC ACID 50203 AMINOGLUTETHIMIDE 50420 ATROPINE 50030 ACETOHEXAMIDE 50205 AMINOHIPPURATE 50430 ATTAPULGITE 50032 ACETOHYDROXAMIC SODIUM 50433 AURANOFIN ACID 50210 AMINOPHYLLINE 50435 AUROTHIOGLUCOSE 50035 ACETONE 50216 AMINOPYRINE 50440 AZATADINE 50040 ACETOPHENAZINE 50220 AMINOSALICYLIC ACID 50444 AZTREONAM 50055 ACETYLCHOLINE 50223 AMIODARONE HCL 50445 AZATHIOPRINE 50060 ACETYLCYSTEINE 50225 AMISOMETRADINE 50446 AZLOCILLIN SODIUM 50065 ACONITE 50230 AMITRIPTYLINE 50447 BACAMPICILLIN 50075 ACRISORCIN 50235 AMMONIA SPIRIT 50450 BACITRACIN 50078 ACYCLOVIR AROMATIC 50455 BACLOFEN 50080 ADENOSINE 50238 AMMONIA STRONG 50460 BALSAM 50083 AGAR 50240 AMMONIATED MERCURY 50465 BANDAGE 50085 ALBUMIN HUMAN 50241 AMMONIUM ACRYLATES 50475 BARBITAL 50088 ALBUTEROL 50242 AMMONIUM ALUM 50480 BARIUM SULFATE 50090 ALCOHOL 50243 AMMONIUM BROMIDE 50485 BCG VACCINE 50093 ALFENTAIL 50244 AMMONIUM CARBONATE 50490 BECLOMETHASONE HYDROCHLORIDE 50245 AMMONIUM CHLORIDE 50492 BEEF EXTRACT 50096 ALGINIC ACID 50246 AMMONIUM ION 50495 BELLADONNA 50097 ALKYL ETHANOL 50248 AMMONIUM 50497 BEMEGRIDE 50103 ALLANTOIN ISOSTEARATE 50498 BENAZEPRIL 50104 ALLOBARBITAL 50249 AMMONIUM PHOSPHATE HYDROCHLORIDE 50105 ALLOPURINOL 50250 AMOBARBITAL 50499 BENACTYZINE 50107 ALMOND OIL 50258 AMOXAPINE 50500 BENDROFLU- 50109 ALOIN 50260 AMOXICILLIN METHIAZIDE 50110 ALPHAPRODINE 50265 AMPHETAMINE 50502 BENOXAPROFEN 50113 ALPRAZOLAM 50270 AMPHOTERICIN 50505 BENOXINATE 50116 ALPROSTADIL 50275 AMPICILLIN 50507 BENTIROMIDE 50120 ALSEROXYLON 50278 AMRINONE LACTATE 50508 BENTONITE 50125 ALUMINUM 50280 AMYL NITRITE 50511 BENZALDEHYDE 50130 ALUMINUM ACETATE 50281 AMYL PHENOL 50515 BENZALKONIUM 50135 ALUMINUM AMMONIUM 50283 AMYLASE CHLORIDE SULFATE 50284 ANETHOLE 50516 BENZENE 50138 ALUMINUM 50285 ANILERIDINE 50518 BENZESTROL CHLORHYDROXY- 50290 ANISE OIL 50520 BENZETHONIUM ALLANTOINATE 50295 ANISINDIONE CHLORIDE 50140 ALUMINUM CHLORIDE 50300 ANISOTROPINE 50525 BENZIN 50145 ALUMINUM HYDROXIDE 50305 ANTAZOLINE 50530 BENZOCAINE 50148 ALUMINUM OXIDE 50310 ANTHRALIN 50538 BENZOIC ACID 50155 ALUMINUM PHOSPHATE 50320 ANTIHEMOPHILIC 50540 BENZOIN 50157 ALUMINUM POTASSIUM FACTOR HUMAN 50545 BENZONATATE SULFATE 50323 ANTIMONY POTASSIUM 50548 BENZOPHENONE 50159 ALUMINUM STEARATE TARTRATE 50550 BENZOYL PEROXIDE 50160 ALUMINUM 50325 ANTIPYRINE 50555 BENZPHETAMINE SUBACETATE 50330 ANTIRABIES SERUM 50557 BENZPYRINIUM 50163 ALUMINUM SULFATE 50335 ANTISEPTIC SOLUTION BROMIDE 50165 AMANTADINE 50338 ANTIVENIN BEE STING 50558 BENZQUINAMIDE 50168 AMARANTH 50360 APOMORPHINE 50560 BENZTHIAZIDE 50565 BENZTROPINE 50742 BUTYLPARABEN 50930 CARPHENAZINE 50570 BENZYL ALCOHOL 50745 CAFFEINE 50933 CASANTHRANOL 50575 BENZYL BENZOATE 50755 CALAMINE 50935 CASCARA 50576 BENZYL CINNAMATE 50758 CALCIFEDIOL 50938 CASEIN 50577 BERACTANT 50760 CALCITONIN 50940 CASTOR OIL 50578 BERBERINE 50770 CALCIUM 50943 CEDAR LEAF OIL 50580 BETA-CAROTENE REPLACEMENT 50945 CEFACLOR 50583 BETAINE AGENTS 50950 CEFADROXIL 50585 BETAMETHASONE 50773 CALCIUM 50955 CEFAMANDOLE 50588 BETAXOLOL HCL GLYCEROPHOSPHATE 50960 CEFAZOLIN 50590 BETAZOLE 50775 CALCIUM ACETATE 50961 CEFTRIAXONE 50595 BETHANECHOL 50776 CALCIUM 50962 CEFOPERAZONE 50605 BILAZO REAGENT 50780 CALCIUM BROMIDE 50963 CEFORANIDE 50610 BILE ACIDS 50785 CALCIUM CARBONATE 50964 CEFOTAXIME SODIUM 50613 BILE SALTS 50800 CALCIUM HYDROXIDE 50965 CEFOXITIN SODIUM 50615 BIOFLAVONOIDS 50802 CALCIUM IODIDE 50966 CEFTAZIDIME 50620 BIOTIN 50803 CALCIUM POLYSULFIDE 50967 CEFUROXIME SODIUM 50625 BIPERIDEN 50804 CALCIUM PROPIONATE 50968 CELLULASE 50630 BISACODYL 50805 CALCIUM SILICATE 50969 CEFOTETAN DISODIUM 50631 BISMUTH ALUMINATE 50806 CALCIUM ION 50975 CELLULOSE 50632 BISMUTH OXIDE 50810 CALCIUM SUCCINATE 50978 CEPHAELINE 50634 BISMUTH SULFONATE 50811 CALCIUM 50980 CEPHALEXIN 50635 BISMUTH ANTI-DIARRHEA PANTOTHENATE 50990 CEPHALORIDINE AGENTS 50818 CALCIUM THIOGLYCOLLATE 50995 CEPHALOTHIN 50636 BISMUTH, INTERNAL 50821 CALCIUM THIOSULFATE 51000 CEPHAPIRIN 50637 BISMUTH, EXTERNAL 50823 CALCIUM UNDECYLENATE 51005 CEPHRADINE 50638 BISMUTH IODIDE 50824 CALJUPUT OIL 51008 CERESIN WAX 50640 BISMUTH SALICYLATE 50835 CALLICREIN 51010 CERIUM OXALATE 50650 BISMUTH 50840 CALUSTERONE 51012 CERULETIDE TRIBROMOPHENATE 50845 CAMPHOR DIETHYLAMINE 50653 BITOLTEROL MESYLATE 50848 CANDELILLA WAX 51015 CETALKONIUM CHLORIDE 50655 BLEOMYCIN 50860 CANTHARIDIN 51016 CETEARETH 50660 BORIC ACID 50865 CAPREOMYCIN 51017 CETEARYL OCTANOATE 50663 BRAN 50866 CAPRYLIC ACID 51018 CETRIMONIUM BROMIDE 50665 BRETYLIUM 50867 CAPSAICIN 51020 CETYL ALCOHOL 50668 BRILLIANT BLUE 50868 CAPSICUM 51021 CETYL ESTERS 50670 BRILLIANT GREEN 50869 CAPTOPRIL 51023 CETYLPYRIDINIUM 50675 BROMELAINS 50870 CARAMEL 51025 CHARCOAL 50679 BROMINE 50873 CARAMIPHEN 51030 CHERRY SYRUP 50680 BROMOCRIPTINE 50874 CARAWAY OIL 51040 CHLORAL HYDRATE 50685 BROMODIPHEN- 50875 CARBACHOL 51045 CHLORAMBUCIL HYDRAMINE 50880 CARBAMAZEPINE 51050 CHLORAMPHENICOL 50687 BROMOPHENOL 50885 CARBARSONE 51053 CHLORCYCLIZINE 50690 BROMPHENIRAMINE 50887 CALCIUMOCARBASPIRIN 51055 CHLORDIAZEPOXIDE 50695 BROWN MIXTURE 50890 CARBAZOCHROME 51060 CHLORHEXIDINE 50698 BUCHU 50895 CARBENICILLIN 51063 CHLORHYDROXY- 50705 BUCLIZINE 50898 CARBETAPENTANE QUINOLONE 50706 BUFFERS 50899 CARBIDOPA 51064 CHLORIDE ION 50708 BUMETANIDE 50900 CARBINOXAMINE 51066 CHLORMEZANONE 50710 BUPIVACAINE 50905 CARBO-FUCHSIN 51068 CHLOROACETIC ACID 50711 BUPRENORPHINE HCL 50906 CABOMERS 51070 CHLOROALLY- 50713 BUSPRIONE HCL 50908 CARBON DIOXIDE HEXAMINIUM CHLORIDE 50714 BUPROPION 50910 CARBON TETRACHLORIDE 51075 CHLOROBUTANOL 50715 BUSULFAN 50912 CARBOXYMETHYL- 51080 CHLOROFORM 50720 BUTABARBITAL CELLULOSE 51085 CHLOROPHYLL 50725 BUTACAINE 50914 CARBROMAL 51090 CHLOROPROCAINE 50728 BUTALBITAL 50915 CARDAMOM 51095 CHLOROQUINE 50730 BUTAMBEN 50920 CARISOPRODOL 51100 CHLOROTHIAZIDE 50733 BUTOCONAZOLE 50923 CARMELLOSE 51105 CHLOROTHYMOL NITRATE 50925 CARMUSTINE 51110 CHLOROTRIANISENE 50740 BUTORPHANOL 50929 CARNITINE 51115 CHLOROXINE 51120 CHLOROXYLENOL 51330 COCONUT OIL 51610 DESLANOSIDE 51125 CHLORPHENESIN 51335 COD & HALIBUT LIVER OIL 51615 DESMOPRESSIN 51130 CHLORPHENIRAMINE 51340 CODEINE 51620 DESONIDE 51145 CHLORPHENTERMINE 51345 COLCHICINE 51625 DESOXIMETASONE 51150 CHLORPROMAZINE 51355 COLESTIPOL 51627 DESOXYCHOLIC ACID 51155 CHLORPROPAMIDE 51358 COLIFORM VACCINE 51630 DESOXYCORTICOSTERONE 51160 CHLORPROTHIXENE 51360 COLISTIN 51633 DETERGENT 51165 CHLORTETRACYCLINE 51365 COLLAGEN DERIVATIVE 51635 DEXAMETHASONE 51170 CHLORTHALIDONE 51375 COLLODION 51638 DEXBROMPHENIRAMINE 51175 CHLORZOXAZONE 51380 COMBINATION 51640 DEXCHLORPHENIRAMINE 51177 CHOLECALCIFEROL PRODUCT(MULTI-VIT/- 51645 DEXPANTHENOL 51180 CHOLERA VACCINE MINERAL) 51647 DEXTRAN 51185 CHOLESTEROL 51381 FIXED COMBINATION 51660 DEXTRANOMER 51190 CHOLESTYRAMINE 51385 CONGO RED 51665 DEXTROAMPHETAMINE 51193 CHOLIC ACID 51390 CONTACT LENS SOLUTION 51670 DEXTROMETHORPHAN 51195 CHOLINE 51393 COPPER 51675 DEXTROSE 51200 CHOLINE SALICYLATE 51395 CORN OIL 51685 DEXTROTHYROXINE 51203 CHONDRUS 51400 CORTICOTROPIN 51686 DIABETIC SUPPLIES, 51205 CHORIONIC 51405 CORTISONE MISCELL GONADOTROPIN 51410 COSYNTROPIN 51688 DIASTASE 51208 CHROMIC CHLORIDE 51415 COTTONSEED OIL 51689 DIATRIZOTE SODIUM 51209 CHROMIUN 51425 CRESOL 51695 DIAZEPAM 51211 CHYMOPAPAIN 51430 CROMOLYN SODIUM 51700 DIAZOXIDE 51215 CHYMOTRYPSIN 51435 CROTAMITON 51705 DIBUCAINE 51218 CICLOPIROX 51440 CRYPTENAMINE 51708 DICHLORALPHENAZONE 51219 CILASTATIN 51443 CUBEB 51709 DICHLORODI- 51220 CIMETIDINE 51445 CUPRIC SULFATE FLUOROMETHANE 51223 CINNAMEDRINE 51450 OXYTETRACYCLINE 51710 DICHLOROTETRA- 51225 CINNAMON OIL 51460 CYCLACILLIN FLUOROETHANE 51227 CINOXACIN 51465 CYCLANDELATE 51712 DICHLOROPHENE 51228 CINOXATE 51470 CYCLOBENZAPRINE 51715 DICHLORPHENAMIDE 51229 CIPROFLOXACIN HCL 51475 CYCLOMETHYCAINE 51720 DICLOXACILLIN 51230 CISPLATIN 51478 CYCLOPENTAMINE 51725 DICUMAROL 51235 CITRIC ACID 51480 CYCLOPENTOLATE 51730 DICYCLOMINE 51240 CITRONELLA OIL 51485 CYCLOPHOSPHAMIDE 51732 DIDANOSINE 51242 CLARITHROMYCIN 51490 CYCLOSERINE 51735 DIENESTROL 51243 CLOBETASOL PROPIONATE 51493 CYCLOSPORINE 51740 DIETARY SUPPLEMENT 51245 CLEMASTINE 51495 CYCLOTHIAZIDE 51745 DIETHYLCARBAMAZINE 51250 CLIDINIUM 51500 CYCLIZINE 51750 DIETHYLPROPION 51255 CLINDAMYCIN 51505 CYCRIMINE 51755 DIETHYLSTILBESTROL 51257 CLOCORTOLONE 51510 CYPROHEPTADINE 51760 DIFLORASONE DIACETATE 51260 CLOFIBRATE 51515 CYSTEINE 51763 DIFlUNISAL 51265 CLOMIPHENE 51518 CYSTINE 51765 DIGALLOYL TRIOLEATE 51270 CLONAZEPAM 51520 CYTARABINE 51770 DIGITALIS 51275 CLONIDINE 51523 D-ALPHA TOCOPHERYL 51775 DIGITOXIN 51280 CLORAZEPATE 51530 DACARBAZINE 51780 DIGOXIN 51285 CLORTERMINE 51535 DACTINOMYCIN 51785 DIHYDROERGOTAMINE 51290 CLOTRIMAZOLE 51540 DANAZOL 51790 DIHYDROTACHYSTEROL 51295 CLOVE OIL 51545 DANTHRON 51792 DIHYDROXYACETONE 51300 CLOXACILLIN 51550 DANTROLENE 51795 DIHYDROXYALUMINUM 51303 CLOZAPINE 51555 DAPSONE AMINOACETATE 51305 COAL TAR 51560 DAUNORUBICIN 51800 DIHYDROXYALUMINUM 51308 COBALAMIN 51567 DEA PHOSPHATE SODIUM CARBONATE 51310
Recommended publications
  • CHAPTER 29 ORGANIC CHEMICALS VI 29-1 Notes 1

    CHAPTER 29 ORGANIC CHEMICALS VI 29-1 Notes 1

    )&f1y3X CHAPTER 29 ORGANIC CHEMICALS VI 29-1 Notes 1. Except where the context otherwise requires, the headings of this chapter apply only to: (a) Separate chemically defined organic compounds, whether or not containing impurities; (b) Mixtures of two or more isomers of the same organic compound (whether or not containing impurities), except mixtures of acyclic hydrocarbon isomers (other than stereoisomers), whether or not saturated (chapter 27); (c) The products of headings 2936 to 2939 or the sugar ethers and sugar esters, and their salts, of heading 2940, or the products of heading 2941, whether or not chemically defined; (d) Products mentioned in (a), (b) or (c) above dissolved in water; (e) Products mentioned in (a), (b) or (c) above dissolved in other solvents provided that the solution constitutes a normal and necessary method of putting up these products adopted solely for reasons of safety or for transport and that the solvent does not render the product particularly suitable for specific use rather than for general use; (f) The products mentioned in (a), (b), (c), (d) or (e) above with an added stabilizer (including an anticaking agent) necessary for their preservation or transport; (g) The products mentioned in (a), (b), (c), (d), (e) or (f) above with an added antidusting agent or a coloring or odoriferous substance added to facilitate their identification or for safety reasons, provided that the additions do not render the product particularly suitable for specific use rather than for general use; (h) The following products, diluted to standard strengths, for the production of azo dyes: diazonium salts, couplers used for these salts and diazotizable amines and their salts.
  • Aldrich FT-IR Collection Edition I Library

    Aldrich FT-IR Collection Edition I Library

    Aldrich FT-IR Collection Edition I Library Library Listing – 10,505 spectra This library is the original FT-IR spectral collection from Aldrich. It includes a wide variety of pure chemical compounds found in the Aldrich Handbook of Fine Chemicals. The Aldrich Collection of FT-IR Spectra Edition I library contains spectra of 10,505 pure compounds and is a subset of the Aldrich Collection of FT-IR Spectra Edition II library. All spectra were acquired by Sigma-Aldrich Co. and were processed by Thermo Fisher Scientific. Eight smaller Aldrich Material Specific Sub-Libraries are also available. Aldrich FT-IR Collection Edition I Index Compound Name Index Compound Name 3515 ((1R)-(ENDO,ANTI))-(+)-3- 928 (+)-LIMONENE OXIDE, 97%, BROMOCAMPHOR-8- SULFONIC MIXTURE OF CIS AND TRANS ACID, AMMONIUM SALT 209 (+)-LONGIFOLENE, 98+% 1708 ((1R)-ENDO)-(+)-3- 2283 (+)-MURAMIC ACID HYDRATE, BROMOCAMPHOR, 98% 98% 3516 ((1S)-(ENDO,ANTI))-(-)-3- 2966 (+)-N,N'- BROMOCAMPHOR-8- SULFONIC DIALLYLTARTARDIAMIDE, 99+% ACID, AMMONIUM SALT 2976 (+)-N-ACETYLMURAMIC ACID, 644 ((1S)-ENDO)-(-)-BORNEOL, 99% 97% 9587 (+)-11ALPHA-HYDROXY-17ALPHA- 965 (+)-NOE-LACTOL DIMER, 99+% METHYLTESTOSTERONE 5127 (+)-P-BROMOTETRAMISOLE 9590 (+)-11ALPHA- OXALATE, 99% HYDROXYPROGESTERONE, 95% 661 (+)-P-MENTH-1-EN-9-OL, 97%, 9588 (+)-17-METHYLTESTOSTERONE, MIXTURE OF ISOMERS 99% 730 (+)-PERSEITOL 8681 (+)-2'-DEOXYURIDINE, 99+% 7913 (+)-PILOCARPINE 7591 (+)-2,3-O-ISOPROPYLIDENE-2,3- HYDROCHLORIDE, 99% DIHYDROXY- 1,4- 5844 (+)-RUTIN HYDRATE, 95% BIS(DIPHENYLPHOSPHINO)BUT 9571 (+)-STIGMASTANOL
  • (12) United States Patent (10) Patent N0.: US 8,343,962 B2 Kisak Et Al

    (12) United States Patent (10) Patent N0.: US 8,343,962 B2 Kisak Et Al

    US008343962B2 (12) United States Patent (10) Patent N0.: US 8,343,962 B2 Kisak et al. (45) Date of Patent: *Jan. 1, 2013 (54) TOPICAL FORMULATION (58) Field of Classi?cation Search ............. .. 514/226.5, 514/334, 420, 557, 567 (75) Inventors: Edward T. Kisak, San Diego, CA (US); See application ?le fOr Complete Search history. John M. NeWsam, La Jolla, CA (US); _ Dominic King-Smith, San Diego, CA (56) References C‘ted (US); Pankaj Karande, Troy, NY (US); Samir Mitragotri, Goleta, CA (US) US' PATENT DOCUMENTS 5,602,183 A 2/1997 Martin et al. (73) Assignee: NuvoResearchOntano (CA) Inc., Mississagua, 6,328,979 2B1 12/2001 Yamashita et a1. 7,001,592 B1 2/2006 Traynor et a1. ( * ) Notice: Subject to any disclaimer, the term of this 7,795,309 B2 9/2010 Kisak eta1~ patent is extended or adjusted under 35 2002/0064524 A1 5/2002 Cevc U.S.C. 154(b) by 212 days. FOREIGN PATENT DOCUMENTS This patent is subject to a terminal dis- W0 WO 2005/009510 2/2005 claimer- OTHER PUBLICATIONS (21) APPI' NO‘, 12/848,792 International Search Report issued on Aug. 8, 2008 in application No. PCT/lB2007/0l983 (corresponding to US 7,795,309). _ Notice ofAlloWance issued on Apr. 29, 2010 by the Examiner in US. (22) Med Aug- 2’ 2010 Appl. No. 12/281,561 (US 7,795,309). _ _ _ Of?ce Action issued on Dec. 30, 2009 by the Examiner in US. Appl. (65) Prior Publication Data No, 12/281,561 (Us 7,795,309), Us 2011/0028460 A1 Feb‘ 3’ 2011 Primary Examiner * Raymond Henley, 111 Related U 5 Application Data (74) Attorney, Agent, or Firm * Foley & Lardner LLP (63) Continuation-in-part of application No.
  • Ricini Oleum

    Ricini Oleum

    PHARMACOGNOSY II PHAR306 6th Semester 5th Lecture Prof. Dr. Müberra Koşar Ass. Prof. Dr. Aybike Yektaoğlu Eastern Mediterranean University Faculty of Pharmacy Department of Pharmacognosy PHARMACEUTICAL FIXED OILS AND ANIMAL FATS FIXED OILS & ANIMAL FATS Amygdalae oleum • “Almond oil” • obtained by crushing of the seeds of two varieties Prunus dulcis var. dulcis or P. dulcis var. amara (Rosaceae) in the cold • Almond oil is obtained in the Mediterranean countries (Italy, France, Spain and North Africa) where its culture is obtained • The only difference between the two varieties is the cyanogenic glycoside content of the var. amara FIXED OILS&ANIMAL FATS Amygdalae oleum • seeds carries 40-55% fixed oil • the refined oil mainly contains oleic acid (62-86%), linoleic (20- 30%), palmitic (4-9%) • Amydalae oleum raffinatum (Almond oil, refined) (Eur.Pu.) • Amydalae oleum virginale (Almond oil, virgin) (Eur.Ph.) • major used in cosmetology and dermatology • used as a carrier in oily injectable preparations FIXED OILS&ANIMAL FATS Arachidis oleum • “Arachis oil, Peanut oil” – “Peanut butter” • Arachis hypogaea (Fabaceae) • cultivated in South America, China, India, Australia, and West Africa • due to various genotypes they vary in fatty acid content • the seeds are cold-pressed • they have similar properties as olive oil • most suitable oil for added for embedding purposes into other oils (e.g. olive oil) FIXED OILS&ANIMAL FATS Arachidis oleum - content • seeds carries 40-50% fixed oil • 50-65% oleic acid • 18-30% linoleic acid • 8-10% palmitic
  • The Anxiomimetic Properties of Pentylenetetrazol in the Rat

    The Anxiomimetic Properties of Pentylenetetrazol in the Rat

    University of Rhode Island DigitalCommons@URI Open Access Dissertations 1980 THE ANXIOMIMETIC PROPERTIES OF PENTYLENETETRAZOL IN THE RAT Gary Terence Shearman University of Rhode Island Follow this and additional works at: https://digitalcommons.uri.edu/oa_diss Recommended Citation Shearman, Gary Terence, "THE ANXIOMIMETIC PROPERTIES OF PENTYLENETETRAZOL IN THE RAT" (1980). Open Access Dissertations. Paper 165. https://digitalcommons.uri.edu/oa_diss/165 This Dissertation is brought to you for free and open access by DigitalCommons@URI. It has been accepted for inclusion in Open Access Dissertations by an authorized administrator of DigitalCommons@URI. For more information, please contact [email protected]. THE ANXIOMIMETIC PROPERTIES OF PENTYLENETETRAZOL IN THE RAT BY GARY TERENCE SHEARMAN A DISSERTATION SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY IN PHARMACEUTICAL SCIENCES (PHARMACOLOGY AND TOXICOLOGY) UNIVERSITY OF RHODE ISLAND 19 80 DOCTOR OF PHILOSOPHY DISSERT.A.TION OF GARY TERENCE SHEAffiil.AN Approved: Dissertation Cormnittee \\ Major Professor ~~-L_-_._dd__· _... _______ _ -~ar- Dean of the Graduate School UNIVERSITY OF RHODE ISLAND 1980 ABSTRACT Investigation of the biological basis of anxiety is ham­ pered by the lack of an appropriate animal model for research purposes. There are no known drugs that cause anxiety in laboratory animals. Pentylenetetrazol (PTZ) produces intense anxiety in human volunteers (Rodin, 1958; Rodin and Calhoun, 1970). Therefore, it was the major objective of this disser- tation to test the hypothesis that the discriminative stimu­ lus produced by PTZ in the rat was related to its anxiogenic action in man. It was also an objective to suggest the neuro- chemical basis for the discriminative stimulus property of PTZ through appropriate drug interactions.
  • Spider Bites

    Spider Bites

    Infectious Disease Epidemiology Section Office of Public Health, Louisiana Dept of Health & Hospitals 800-256-2748 (24 hr number) www.infectiousdisease.dhh.louisiana.gov SPIDER BITES Revised 6/13/2007 Epidemiology There are over 3,000 species of spiders native to the United States. Due to fragility or inadequate length of fangs, only a limited number of species are capable of inflicting noticeable wounds on human beings, although several small species of spiders are able to bite humans, but with little or no demonstrable effect. The final determination of etiology of 80% of suspected spider bites in the U.S. is, in fact, an alternate diagnosis. Therefore the perceived risk of spider bites far exceeds actual risk. Tick bites, chemical burns, lesions from poison ivy or oak, cutaneous anthrax, diabetic ulcer, erythema migrans from Lyme disease, erythema from Rocky Mountain Spotted Fever, sporotrichosis, Staphylococcus infections, Stephens Johnson syndrome, syphilitic chancre, thromboembolic effects of Leishmaniasis, toxic epidermal necrolyis, shingles, early chicken pox lesions, bites from other arthropods and idiopathic dermal necrosis have all been misdiagnosed as spider bites. Almost all bites from spiders are inflicted by the spider in self defense, when a human inadvertently upsets or invades the spider’s space. Of spiders in the United States capable of biting, only a few are considered dangerous to human beings. Bites from the following species of spiders can result in serious sequelae: Louisiana Office of Public Health – Infectious Disease Epidemiology Section Page 1 of 14 The Brown Recluse: Loxosceles reclusa Photo Courtesy of the Texas Department of State Health Services The most common species associated with medically important spider bites: • Physical characteristics o Length: Approximately 1 inch o Appearance: A violin shaped mark can be visualized on the dorsum (top).
  • The In¯Uence of Medication on Erectile Function

    The In¯Uence of Medication on Erectile Function

    International Journal of Impotence Research (1997) 9, 17±26 ß 1997 Stockton Press All rights reserved 0955-9930/97 $12.00 The in¯uence of medication on erectile function W Meinhardt1, RF Kropman2, P Vermeij3, AAB Lycklama aÁ Nijeholt4 and J Zwartendijk4 1Department of Urology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; 2Department of Urology, Leyenburg Hospital, Leyweg 275, 2545 CH The Hague, The Netherlands; 3Pharmacy; and 4Department of Urology, Leiden University Hospital, P.O. Box 9600, 2300 RC Leiden, The Netherlands Keywords: impotence; side-effect; antipsychotic; antihypertensive; physiology; erectile function Introduction stopped their antihypertensive treatment over a ®ve year period, because of side-effects on sexual function.5 In the drug registration procedures sexual Several physiological mechanisms are involved in function is not a major issue. This means that erectile function. A negative in¯uence of prescrip- knowledge of the problem is mainly dependent on tion-drugs on these mechanisms will not always case reports and the lists from side effect registries.6±8 come to the attention of the clinician, whereas a Another way of looking at the problem is drug causing priapism will rarely escape the atten- combining available data on mechanisms of action tion. of drugs with the knowledge of the physiological When erectile function is in¯uenced in a negative mechanisms involved in erectile function. The way compensation may occur. For example, age- advantage of this approach is that remedies may related penile sensory disorders may be compen- evolve from it. sated for by extra stimulation.1 Diminished in¯ux of In this paper we will discuss the subject in the blood will lead to a slower onset of the erection, but following order: may be accepted.
  • The Natural Compounds Atraric Acid and N-Butylbenzene-Sulfonamide

    The Natural Compounds Atraric Acid and N-Butylbenzene-Sulfonamide

    The natural compounds atraric acid and N-butylbenzene-sulfonamide as antagonists of the human androgen receptor and inhibitors of prostate cancer cell growth Daniela Roell, Aria Baniahmad To cite this version: Daniela Roell, Aria Baniahmad. The natural compounds atraric acid and N-butylbenzene-sulfonamide as antagonists of the human androgen receptor and inhibitors of prostate cancer cell growth. Molec- ular and Cellular Endocrinology, Elsevier, 2010, 332 (1-2), pp.1. 10.1016/j.mce.2010.09.013. hal- 00654968 HAL Id: hal-00654968 https://hal.archives-ouvertes.fr/hal-00654968 Submitted on 24 Dec 2011 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Accepted Manuscript Title: The natural compounds atraric acid and N-butylbenzene-sulfonamide as antagonists of the human androgen receptor and inhibitors of prostate cancer cell growth Authors: Daniela Roell, Aria Baniahmad PII: S0303-7207(10)00474-0 DOI: doi:10.1016/j.mce.2010.09.013 Reference: MCE 7644 To appear in: Molecular and Cellular Endocrinology Received date: 29-6-2010 Revised date: 3-9-2010 Accepted date: 27-9-2010 Please cite this article as: Roell, D., Baniahmad, A., The natural compounds atraric acid and N-butylbenzene-sulfonamide as antagonists of the human androgen receptor and inhibitors of prostate cancer cell growth, Molecular and Cellular Endocrinology (2010), doi:10.1016/j.mce.2010.09.013 This is a PDF file of an unedited manuscript that has been accepted for publication.
  • ALLERGIC REACTIONS/ANAPHYLAXIS Connie J

    ALLERGIC REACTIONS/ANAPHYLAXIS Connie J

    Northwest Community EMS System Paramedic Education Program ALLERGIC REACTIONS/ANAPHYLAXIS Connie J. Mattera, M.S., R.N., EMT-P Reading assignments Text-Vol.1 pp. 235, 1272-1276 SOP: Allergic Reactions/ Anaphylactic Shock Assumed knowledge: Drugs: Epinephrine 1:1,000, 1:10,000; albuterol, ipratropium, dopamine, glucagon KNOWLEDGE OBJECTIVES Upon reading the assigned text assignments and completion of the class and homework questions, each participant will independently do the following with at least an 80% degree of accuracy and no critical errors: 1. Define allergic reaction. 2. Describe the incidence, morbidity and mortality of allergic reactions and anaphylaxis. 3. Identify risk factors that predispose a patient to anaphylaxis. 4. Explain the physiology of the immune system following exposure to an allergen including activation of histamine receptors and the formation of antibodies. 5. Discuss the pathophysiology of allergic reactions and anaphylaxis. 6. Describe the common modes by which allergens enter the body. 7. Compare and contrast natural and acquired and active vs. passive immunity. 8. Identify antigens most frequently associated with anaphylaxis. 9. Differentiate the clinical presentation and severity of risk for a mild, moderate and severe allergic reaction with an emphasis on recognizing an anaphylactic reaction. 10. Integrate the pathophysiologic principles of anaphylaxis with treatment priorities. 11. Sequence care per SOP for patients with mild, moderate and severe allergic reactions. CJM: S14 NWC EMSS Paramedic Education Program ALLERGIC REACTIONS/ANAPHYLAXIS Connie J. Mattera, M.S., R.N., EMT-P I. Immune system A. Principal body system involved in allergic reactions. Others include the cutaneous, cardiovascular, respiratory, nervous, and gastrointestinal systems.
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017

    Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017

    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
  • Action of Ammonium Chloride Upon Silicates

    Action of Ammonium Chloride Upon Silicates

    Bulletin No. 207 Series E, Chemistry and Physics, 36 DEPARTMENT OF TEiE INTERIOR UNITED STATES GEOLOGICAL SURVEY CHARLES D. WALCOTT, DIRECTOR THE ACTION OF AMMONIUM CHLORIDE UPON SILICATES BY AND GKKOKG-IE Srj::ir, WASHINGTON GOVERNMEN.T PllINTING OFFICE 1902 CONTENTS. Page. Introductory statement......--..-..---.--.------.--.-..--.-.-----------. 7 Analcite-.....-.-.-.--.-.....-.--.'--------....--.-.--..._.-.---.-...---.--. 8 Leucite .....................'.................-....................^-..... 16 The constitution of analcite and leucite.........-..--.-..--...--.---------. 17 Pollucite---. ............................................................ 21 Natrolite--------------------------..-..-----------------.------ --------- 22 Scolecite ................,.:............-.....-.................--.--.... 24 Prehnite .....--.-............--.------------------------------ --------- 25 The trisilicic acids-.--.-.--..---..........-._-----...-.........-...----.- 26 Stilbite.............-..................-....-.-.-----...--.---.......... 29 Henlandite .......... .......................---.-..-.-..-...-----.--..--.. 81 Chabazite............................................................... 32 Thoinsonite...-.-.-..-...._.................---...-.-.-.----..-----..--.. 34 Lanmontite -.-.------.-..-------------.-..-.-..-.-------.-.-----........ 35 Pectolite ......:......... ......................................'.......;.., 36 Wollastonite ....'............................ ................:........... 39 Apophyllite. _.--._..._-....__.....:......___-------------....----..-...._
  • Environmental Protection Agency § 117.3

    Environmental Protection Agency § 117.3

    Environmental Protection Agency § 117.3 (4) Applicability date. This paragraph TABLE 117.3—REPORTABLE QUANTITIES OF (i) is applicable beginning on February HAZARDOUS SUBSTANCES DESIGNATED PUR- 6, 2020. SUANT TO SECTION 311 OF THE CLEAN (j) Process waste water means any WATER ACT—Continued water which, during manufacturing or Cat- RQ in pounds processing, comes into direct contact Material egory (kilograms) with or results from the production or use of any raw material, intermediate Ammonium benzoate ...................... D ...... 5,000 (2,270) Ammonium bicarbonate .................. D ...... 5,000 (2,270) product, finished product, byproduct, Ammonium bichromate ................... A ....... 10 (4.54) or waste product. Ammonium bifluoride ...................... B ....... 100 (45.4) Ammonium bisulfite ......................... D ...... 5,000 (2,270) [44 FR 50776, Aug. 29, 1979, as amended at 58 Ammonium carbamate .................... D ...... 5,000 (2,270) FR 45039, Aug. 25, 1993; 65 FR 30904, May 15, Ammonium carbonate ..................... D ...... 5,000 (2,270) 2000; 80 FR 37112, June 29, 2015; 83 FR 5208, Ammonium chloride ........................ D ...... 5,000 (2,270) Feb. 6, 2018] Ammonium chromate ...................... A ....... 10 (4.54) Ammonium citrate dibasic ............... D ...... 5,000 (2,270) Ammonium fluoborate ..................... D ...... 5,000 (2,270) § 117.2 Abbreviations. Ammonium fluoride ......................... B ....... 100 (45.4) NPDES equals National Pollutant Ammonium hydroxide ..................... C